“… In patients with signs and symptoms compatible with severe or critical COVID-19 for the diagnosis of COVID-19 infection, we suggest the use of NAAT in nasopharyngeal swab samples versus NAAT in saliva samples for diagnosis of COVID-19. | Weak against | Very low | [ 13 , 92 , [98] , [99] , [100] , [101] , [102] , [103] , [104] , [105] , [106] , [107] , [108] , [109] , [110] , [111] , [112] , [113] , [114] , [115] , [116] ] | 22 | In patients with signs and symptoms compatible with COVID-19 of equal or less than 7 days onset , should saliva sampling be used, compared with nasopharyngeal swab sampling for diagnosis of COVID-19 with NAAT? | In patients with signs and symptoms compatible with COVID-19 of equal or less than 7 days-onset, we suggest the use of NAAT in saliva samples versus NAAT in nasopharyngeal swab samples for diagnosis of COVID-19. |
…”